These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 28631217

  • 1. 24-Month Open-Label Teriparatide Once-Weekly Efficacy Research Trial Examining Bone Mineral Density in Subjects with Primary Osteoporosis and High Fracture Risk.
    Sugimoto T, Shiraki M, Fukunaga M, Hagino H, Sone T, Nakano T, Kishimoto H, Ito M, Yoshikawa H, Kishida M, Irie C, Nakamura T.
    Adv Ther; 2017 Jul; 34(7):1727-1740. PubMed ID: 28631217
    [Abstract] [Full Text] [Related]

  • 2. Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial.
    Sugimoto T, Shiraki M, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Kuroda T, Nakamura T.
    Curr Med Res Opin; 2013 Mar; 29(3):195-203. PubMed ID: 23259702
    [Abstract] [Full Text] [Related]

  • 3. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.
    Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Yoshikawa H, Nishizawa Y, Fujita T, Shiraki M.
    J Clin Endocrinol Metab; 2012 Sep; 97(9):3097-106. PubMed ID: 22723322
    [Abstract] [Full Text] [Related]

  • 4. Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study.
    Sugimoto T, Shiraki M, Fukunaga M, Kishimoto H, Hagino H, Sone T, Nakano T, Ito M, Yoshikawa H, Minamida T, Tsuruya Y, Nakamura T.
    Osteoporos Int; 2019 Nov; 30(11):2321-2331. PubMed ID: 31392401
    [Abstract] [Full Text] [Related]

  • 5. A multicenter, randomized, rater-blinded, parallel-group, phase 3 study to compare the efficacy, safety, and immunogenicity of biosimilar RGB-10 and reference once-daily teriparatide in patients with osteoporosis.
    Hagino H, Narita R, Yokoyama Y, Watanabe M, Tomomitsu M.
    Osteoporos Int; 2019 Oct; 30(10):2027-2037. PubMed ID: 31243480
    [Abstract] [Full Text] [Related]

  • 6. Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study.
    Sumida K, Ubara Y, Hoshino J, Mise K, Hayami N, Suwabe T, Kawada M, Imafuku A, Hiramatsu R, Hasegawa E, Yamanouchi M, Sawa N, Takaichi K.
    Osteoporos Int; 2016 Apr; 27(4):1441-1450. PubMed ID: 26525045
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of once-weekly teriparatide in patients with glucocorticoid-induced osteoporosis: the TOWER-GO study.
    Tanaka I, Tanaka Y, Soen S, Oshima H.
    J Bone Miner Metab; 2021 May; 39(3):446-455. PubMed ID: 33211212
    [Abstract] [Full Text] [Related]

  • 8. Treatment responses with once-weekly teriparatide therapy for osteoporosis.
    Shiraki M, Ueda S, Sugimoto T, Kuroda T, Nakamura T.
    Osteoporos Int; 2016 Oct; 27(10):3057-62. PubMed ID: 27234671
    [Abstract] [Full Text] [Related]

  • 9. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
    Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C, ACTIVE Study Investigators.
    JAMA; 2016 Aug 16; 316(7):722-33. PubMed ID: 27533157
    [Abstract] [Full Text] [Related]

  • 10. Once-weekly teriparatide reduces the risk of vertebral fracture in patients with various fracture risks: subgroup analysis of the Teriparatide Once-Weekly Efficacy Research (TOWER) trial.
    Nakano T, Shiraki M, Sugimoto T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Kuroda T, Nakamura T.
    J Bone Miner Metab; 2014 Jul 16; 32(4):441-6. PubMed ID: 24213216
    [Abstract] [Full Text] [Related]

  • 11. [Once-weekly teriparatide treatment on osteoporosis].
    Nakano T.
    Clin Calcium; 2014 Jan 16; 24(1):100-5. PubMed ID: 24369286
    [Abstract] [Full Text] [Related]

  • 12. Changes in bone mineral density, bone turnover markers, and vertebral fracture risk reduction with once weekly teriparatide.
    Tanaka S, Kuroda T, Sugimoto T, Nakamura T, Shiraki M.
    Curr Med Res Opin; 2014 May 16; 30(5):931-6. PubMed ID: 24392946
    [Abstract] [Full Text] [Related]

  • 13. A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05.
    Hagino H, Sugimoto T, Tanaka S, Sasaki K, Sone T, Nakamura T, Soen S, Mori S.
    Osteoporos Int; 2021 Nov 16; 32(11):2301-2311. PubMed ID: 34002252
    [Abstract] [Full Text] [Related]

  • 14. Assessing the Effects of Teriparatide Treatment on Bone Mineral Density, Bone Microarchitecture, and Bone Strength.
    Kleerekoper M, Greenspan SL, Lewiecki EM, Miller PD, Kendler DL, Maricic M, Keaveny TM, Kopperdahl DL, Ruff VA, Wan X, Janos B, Krohn K.
    J Bone Joint Surg Am; 2014 Jun 04; 96(11):e90. PubMed ID: 24897747
    [Abstract] [Full Text] [Related]

  • 15. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
    Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, Dalsky GP, Marcus R.
    N Engl J Med; 2007 Nov 15; 357(20):2028-39. PubMed ID: 18003959
    [Abstract] [Full Text] [Related]

  • 16. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R.
    Bone; 2006 Dec 15; 39(6):1268-75. PubMed ID: 16884968
    [Abstract] [Full Text] [Related]

  • 17. Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases.
    Miyauchi A, Matsumoto T, Sugimoto T, Tsujimoto M, Warner MR, Nakamura T.
    Bone; 2010 Sep 15; 47(3):493-502. PubMed ID: 20580870
    [Abstract] [Full Text] [Related]

  • 18. Renal Phosphate Reabsorption is Correlated with the Increase in Lumbar Bone Mineral Density in Patients Receiving Once-Weekly Teriparatide.
    Takeuchi Y, Kuroda T, Sugimoto T, Shiraki M, Nakamura T.
    Calcif Tissue Int; 2016 Feb 15; 98(2):186-92. PubMed ID: 26478225
    [Abstract] [Full Text] [Related]

  • 19. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S.
    J Bone Miner Res; 2011 Mar 15; 26(3):503-11. PubMed ID: 20814967
    [Abstract] [Full Text] [Related]

  • 20. Achieving osteoporosis treat-to-target goals with teriparatide or alendronate: sub-analysis of Japanese Osteoporosis Intervention Trial-05 (JOINT-05).
    Hagino H, Tanaka S, Kuroda T, Mori S, Soen S.
    J Bone Miner Metab; 2024 May 15; 42(3):382-388. PubMed ID: 38755328
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.